Advertisement
Document › Details
bioMérieux S.A.. (4/1/19). "Press Release: University of Antwerp, bioMérieux, and Wellcome Trust to Coordinate VALUE-Dx, a European Public-Private Partnership to Fight Antimicrobial Resistance through Diagnostics". Antwerp, London & Marcy l’Eoile.
Region | Europe | |
Organisation | bioMérieux S.A. (Euronext: BIM) | |
Group | Mérieux (Group) | |
Organisation 2 | Innovative Medicines Initiative (IMI JU + IMI2 JU) | |
Today | Innovative Health Initiative (IHI JU) | |
Group | Innovative Health Initiative (IHI JU) | |
Product | diagnostics (medical/biological) | |
Product 2 | antibiotic | |
Person | Miller, Mark (Mérieux 201210– CMO at bioMérieux) | |
The University of Antwerp, bioMérieux and Wellcome Trust today announced the launch of VALUE-Dx, the first Innovative Medicines Initiative (IMI) project initiated by six in vitro diagnostic companies who join forces with 20 non-industry partners to combat antimicrobial resistance (AMR) and improve patient outcomes. The purpose of VALUE-Dx is to transform medical practice to achieve more personalised, evidence-based antibiotic prescription and use in community care settings through the widespread use of clinical and cost-effective innovative diagnostic strategies. VALUE-Dx is co-funded by the European Commission (IMI), the Wellcome Trust and private companies, with a total budget of around 14 million euros over 4 years.
Diagnostics are deemed instrumental in guiding health care professionals in treating infectious diseases. However, in community care settings antibiotics are often overused and unnecessarily prescribed, accelerating AMR. VALUE-Dx is a European-wide approach to generate evidence on the medical, economic, and public health value of diagnostics in tackling AMR. It will focus on acute respiratory tract infections acquired in community care settings as they are the most frequent cause of medical consultation and inappropriate antibiotic use. The outcomes of VALUE-Dx could apply to other common infections such as urinary tract infections, blood stream infections, and hospital-acquired respiratory tract infections.
According to Dr. Pierre Meulien, Executive Director, Innovative Medicines Initiative (IMI), “Diagnostics are an essential element in the fight against AMR. I am delighted that IMI is supporting a project that, for the first time, has been conceived by representatives of the diagnostics sector and includes world renowned experts from a wide range of academic disciplines. Only by pooling expertise and working together in this way can we hope to address major challenges like AMR”.
“VALUE-Dx is a unique multidisciplinary consortium, with participation of clinicians, microbiologists, health economists, social scientists, and industry”, states Professor Dr. Goossens of the University of Antwerp and leader of this project. “It should help to build the medical and economic case for rapid diagnostics as a public good in the fight against antibiotic resistance”.
“Wellcome is very excited to support this European project”, says Tim Jinks of Wellcome Trust. “Diagnostics are an essential tool to help us tackle AMR, but in order to realise their full potential, we need to be using them much more widely than we currently are. Community care settings are often the first point of care for many people with common infectious diseases, and better use of diagnostics in these settings could significantly reduce unnecessary prescribing of antibiotics. The VALUE-Dx project will allow us to develop deep understanding of the economic, regulatory and policy value determinants of medical diagnostics and help drive the uptake of innovative diagnostic tools into everyday clinical use”.
“Diagnostic tests provide actionable information that are instrumental to enable reasonable use of antimicrobials”, explains Mark Miller, Executive Vice President and Chief Medical Officer at bioMérieux. “The diagnostic industry has a key role to play in the battle against AMR, and together we will be stronger to fight this global public health threat. We are convinced that the VALUE-Dx project will be a game changer to show the true medical and economic value of diagnostics to support antibiotic stewardship and preserve the efficacy of these medications for improving patient care today and for future generations”.
The VALUE-Dx kick-off meeting is taking place in Madrid, Spain, from April 1 to April 4 and brings together major stakeholders and key experts in the field of diagnostics and AMR.
Contact person:
Herman Goossens, MD, PhD Laboratory of Medical Microbiology
Universiteitsplein 1
B-2610 Antwerp - Belgium
Herman.Goossens@uza.be
+32 475 327344
Project coordination team:
Herman Goossens, MD, PhD
University of Antwerp
Herman.Goossens@uza.be
Tim Jinks
The Wellcome Trust London, UK
t.jinks@wellcome.ac.uk
Philippe Cleuziat
bioMérieux
Lyon, France
philippe.cleuziat@biomerieux.com
The public-private partnership includes 26 partners: Academia: The Health Corporation – RAMBAM, University of Antwerp, Universidad De La Rioja, University of Edinburgh, University Hospital Antwerp, University Medical Center Utrecht, Universitair Medisch Centrum Groningen, University of Oxford, University of Verona
Industry: Accelerate Diagnostics, Alere (Abbott), Becton-Dickinson, bioMérieux, Bio-Rad France, Janssen Diagnostics
Professional and other types of organisations: Berry Consultants, Bioaster, Boston University, European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases, Foundation for Innovative New Diagnostics, Fondazione PENTA, Gesundheit Österreich GmbH, Integrated Biobank of Luxembourg, National Institute for Health and Care Excellence, Organisation for Economic Co-operation and Development, Wellcome Trust, ZonMw
Record changed: 2023-06-05 |
Advertisement
More documents for Mérieux (Group)
- [1] Mérieux NutriSciences Corporation. (10/7/24). "Press Release: Mérieux NutriSciences Enters Agreement to Acquire Worldwide Food Testing Business of Bureau Veritas". Chicago, IL....
- [2] bioMérieux S.A.. (10/19/23). "Press Release: bioMérieux Makes Strategic Investment in Oxford Nanopore". Oxford & Marcy-l’Etoile....
- [3] bioMérieux S.A.. (4/14/23). "Press Release: Oxford Nanopore and bioMérieux to Enter into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics". Oxford & Marcy-l’Etoile....
- [4] InDevR, Inc.. (1/17/23). "Press Release: InDevR Raises $9 Million in Series B Financing and Partners with bioMérieux". Boulder, CO....
- [5] Weezion SAS. (6/1/22). "Press Release: Weezion, a French MedTech Start-up, Announces Capital Investment from bioMérieux". Lyon....
- [6] bioMérieux S.A.. (3/18/22). "Press Release: bioMérieux Receives FDA 510(k) Clearance for Its VITEK MS PRIME New MALDI-TOF Mass Spectrometry Identification System". Marcy l’Étoile....
- [7] bioMérieux S.A.. (6/6/19). "Press Release: bioMérieux Increases Its Holding in Hybiome from 54% to 67%". Marcy l’Étoile....
- [8] bioMérieux S.A.. (4/24/19). "Press Release: bioMérieux – First-Quarter 2019 Business Review". Marcy l’Étoile....
- [9] bioMérieux S.A.. (4/15/19). "Press Release: “Global-PPS”, a Survey of Antibiotic Use and Bacterial Resistance in Hospitals Worldwide, Tops the 200,000 Patients". Marcy l’Étoile & Antwerp....
- [10] bioMérieux S.A.. (3/19/19). "Press Release: Baxter and bioMérieux Announce Collaboration to Improve Identification and Treatment of Acute Kidney Injury". Deerfield, IL & Marcy l’Etoile....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com
Advertisement
» top